FIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Donoho et al.

Application No.: 09/691,344

Filed: 10/18/00

Title: Novel Human Proteins and Polynucleotides

Encoding the Same

Attorney Docket No.: LEX-0071-USA

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Group Art Unit: 1653

Examiner: Rita Mitra

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("the Notice"),
mailed December 17, 2001 in connection with the above-identified application, Applicants
submit herewith: (i) a Sequence Listing in computer readable form pursuant to 37 C.F.R.
§1.821(e); (ii) a Verified Statement Concerning Sequence Listing Under 37 C.F.R. §
1.821(f) and (iii) a replacement copy of sequence listing as originally submitted.
Applicants respectfully request the entry of the computer readable form of the Sequence
Listing into the file.

With regard to the statement on the Notice regarding Applicants alleged failure to provide an initial copy of the Sequence Listing as a separate part of the disclosure on paper copy, as required under 37 C.F.R. § 1.821(c), Applicants note for the record that a paper copy of the Sequence Listing was originally submitted with the application as filed on October 18, 2000, as evidenced by the return postcard received from the Patent and Trademark Office ("The Office"), a copy of which is included herewith. Applicants submit

FW, 23,02

that the request for an original paper copy of the Sequence Listing was made in error, or that the copy of the Sequence Listing as originally filed has been misplaced by the Office. Therefore, Applicants believe that an amendment, as requested in the Notice, is not necessary.

However, in order to attempt to comply with the Notice within the time period set for response, Applicants are submitting a replacement copy of the Sequence Listing, which was originally submitted with the application on October 18, 2000. The present document is a complete response to the Notice. Applicants believe that no fees are due in connection with this response. However, the Commissioner is authorized to charge any required fees to Deposit Account No. 50-0892. Should Examiner Mitra have any further questions concerning the present application, a telephone call to the undersigned

PApplicants' representative is earnestly solicited.

<u>January 16, 2002</u>

Date

Respectfully submitted,

Lance K. Ishimoto Reg. No. 41,071

Reg. No. 41,866

AVID W. HISLER

LEXICON GENETICS INCORPORATED 4000 Research Forest Drive The Woodlands, TX 77381 (281) 863-3333



box Patent Application
Express Mail No.: <u>FL672756158US</u>
II S Appl Ser No. to he skylighter
Inventors: Denote Turner, News, Friedrich, Zambrowicz, Sands
Title: Novels from the terms of tolyhurdistrous
Frealing the same
Attorney Docket No.: LEX-CO71-With
Specification 25 pages total (23 pages spec; 1 claim page(s); 1 page Absti
Transmittal Letter (original and copy)
Drawings (pages; number of drawings)
V Sections (7 pages)
Other: return postcard; unsigned Declaration; Small Entity Statement-
Other: return postcard, unsigned Deciaration, Grands
50084425
[10/30/00-dr] []

GAU/1653

PTO/SB/21 (12-97)

COPY OF PAPERS ORIGINALLY FILED

į

.

Approval for use through 9/30/00. OMB 0651-0031

Patient and Trademark Office: U.S. DEPARTMENT OF COMMERCE

inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/691,344 **Application Number** 10/18/00 **TRANSMITTAL** Filing Date Donoho **First Named Inventor FORM** FEB 0 7 2002 1653 **Group Art Unit** (to be used for all correspondence after initial TECH CENTER 16 0/2900 R: Mitra Examiner Name filing) LEX-0071-USA Attorney Docket Number Total Number of Pages in This ----15 Submission ENCLOSURES (check all that apply) Assignment Papers After Allowance Communication (for an Application) to Group Fee Transmittal Form Appeal Communications to Board of Appeals and Interferences Drawing(s) Fee Attached Appeal Communications to Group Licensing-related Papers Amendment/Response (Appeal Notice, Brief, Reply Brief) Petition Routing Slip (PTO/SB/69) and Accompanying Petition **Proprietary Information** After Final To Convert a Provisional Application Status Letter Affidavits/declaration(s Power of Attorney, Revocation Change of Correspondence Address Additional Enclosure(s) (please identify below): **Extension of Time Request** return postcard Express Abandonment Terminal Disclaimer Verified Statement and Sequence Request ist on Diskette Information Disclosure Small Entity Statement Copy of sequence listing (7 pages) Copy of original S/N postcard Statement **Certified Copy of Priority** Request of Refund Copy of Notice to Comply Document(s) Response to Notice to Comply Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Lance K. Ishimoto, Reg. No. 41,866 Firm _exicon Genetics Incorporated Individual name DAVID W. HIBLER Tonce K. Chemoto by Davil W. Debler Signature REB. NO. 41,071 January 16, 2002 Date **CERTIFICATE OF MAILING** I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an January 16, 2002 envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: Nancy Stacey Typed or printed name January 16, 2002 Date Signature

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

- PRINCIPLONING	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/691,344	10/18/2000	Gregory Donoho	LEX-0071-USA	3961
24231 7590 12/17/2001 LEXICON GENETICS INCORPORATED 4000 RESEARCH FOREST DRIVE THE WOODLANDS, TX 77381		TED	EXAM	INER
			MITRA	, RITA
THE WOODL	ANDS, 1X 77301	MIC	ART UNIT	PAPER NUMBER
			1653	0 2
			DATE MAILED: 12/17/2001	יו

DATE MAILED: 12/17/2001

 $\frac{due}{kmc} \frac{11k/62}{kl}$ Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED

Per. H

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.usplo.gov

APPLICATION NO./ CONTROL NO. 09/691344 FILING DATE 10/18/2000 FIRST NAMED INVENTOR /
Gregory Donoho

ATTORNEY DOCKET NO. LEX-0071-USA

EXAMINER

Rita Mitra

RECEIVED

ART UNIT PAPER

6

1653

DATE MAILED:

TECH CENTER 1600/2900

FEB 0 7 2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Rita Mitra** whose telephone number is (703) 605-1211. The examiner can normally be reached on weekdays from 9:30 to 6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached at (703) 308-2923. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

CHRISTOPHER S. F. LOW

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Applicant(s) Application No. Donoho et al. 09/691344 **Notice to Comply Art Unit** Examiner 1653 Rita Mitra, Ph. D. NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)). The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): ☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). ☑ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other: Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where

For questions regarding compliance to these requirements, please contact:

applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

1.825(d).

Technical Assistance......703-287-0200

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY